Literature DB >> 7709324

Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?

J S Moran1.   

Abstract

BACKGROUND: The efficacy of new antimicrobial regimens against Neisseria gonorrhoeae infection of sites other than the urethra and cervix is rarely adequately assessed. GOAL OF THIS STUDY: To learn whether modern antigonococcal agents eradicate infections at some mucosal sites less reliably than at others. STUDY
DESIGN: This was a systematic review of published therapeutic trials of various antimicrobial regimens for the biological cure of uncomplicated mucosal Neisseria gonorrhoeae infections. Data were aggregated by treatment regimen and the cure rates were calculated by site of infection.
RESULTS: Of 16,737 infections, 96.4% were cured--female urethra, 98.4%; male urethra, 96.4%; cervix, 98.0%; female pharynx, 83.7%; male pharynx, 79.2%; female rectum, 97.9%; and male rectum, 95.3%. The differences between the cure rates at the pharynx and at all other sites were statistically significant in the crude analysis and after stratifying by treatment regimen.
CONCLUSION: Modern antigonococcal regimens highly effective against infection of the urethra are highly effective at the cervix and rectum as well, but pharyngeal infections are more difficult to cure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7709324     DOI: 10.1097/00007435-199501000-00007

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  31 in total

Review 1.  Preparing for an era of untreatable gonorrhea.

Authors:  Lindley A Barbee
Journal:  Curr Opin Infect Dis       Date:  2014-06       Impact factor: 4.915

Review 2.  Antibiotic treatment of gonorrhoea--clinical evidence for choice.

Authors:  C Bignell
Journal:  Genitourin Med       Date:  1996-10

Review 3.  The diagnosis of oropharyngeal gonorrhoea.

Authors:  D Barlow
Journal:  Genitourin Med       Date:  1997-02

Review 4.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.

Authors:  Magnus Unemo; Daniel Golparian; Vegard Skogen; Anne Olaug Olsen; Harald Moi; Gaute Syversen; Stig Ove Hjelmevoll
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

6.  Clonally related Neisseria gonorrhoeae isolates with decreased susceptibility to the extended-spectrum cephalosporin cefotaxime in Amsterdam, the Netherlands.

Authors:  Raymond Heymans; Sylvia M Bruisten; Daniel Golparian; Magnus Unemo; Henry J C de Vries; Alje P van Dam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

7.  Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; Negusse Ocbamichael; Angela LeClair; Matthew R Golden
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 8.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2014-02-21

Review 9.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

Review 10.  Gonorrhoea.

Authors:  John S Moran
Journal:  BMJ Clin Evid       Date:  2007-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.